Pharmacogenomic Evaluation of Antihypertensive Responses
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
Sponsor: University of Florida
This PHASE4 trial investigates Hypertension and is currently completed. University of Florida leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Oct 2017 [monthly]
Completed PHASE4
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Florida
For direct contact, visit the study record on ClinicalTrials.gov .